Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Moderate to Severe Thyroid Eye Disease
NCT05015127Phase 3Unknown
- Sponsor
- Harbour BioMed
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of batoclimab in thyroid eye disease (TED) (4 arms), sponsored by Harbour BioMed. Primary endpoint: Proptosis responder rates at 12 weeks. Status: unknown.
02
Drugs
batoclimab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05015127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015127.